Topical immunomodulators in dermatology

Journal of Postgraduate Medicine

Volumn 50, Issue 2, 2004, Pages 131-139

  Khandpur, Sujay ^a   Sharma, V K ^a   Sumanth, K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Dermatological diseases; Topical immunomodulator

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ALPHA INTERFERON; BCG VACCINE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CYCLOSPORIN A; DIPHENCYPRONE; DITHRANOL; DRUG VEHICLE; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8 RECEPTOR; NITROBENZENE DERIVATIVE; PIMECROLIMUS; PLACEBO; PREDNISOLONE; RAPAMYCIN; RESIQUIMOD; SQUARIC ACID DIBUTYL ESTER; STEROID; TACROLIMUS; TACROVATE; TACROVATE FORTE; TACROZ; TACROZ FORTE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR; ZINC OXIDE; ZINC SULFATE; ZINCODERM;

ALOPECIA AREATA; ATOPIC DERMATITIS; BEHCET DISEASE; BOWENOID PAPULOSIS; BURNING SENSATION; CHILL; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTACT ALLERGY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSKERATOSIS; ECZEMA; ERYTHEMA; ERYTHEMA MULTIFORME; FEVER; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; HEADACHE; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; IMMUNE RESPONSE; IMMUNOREGULATION; KELOID; LEUKODERMA; LICHEN PLANUS; LONG TERM CARE; LUPUS ERYTHEMATOSUS; LYMPHADENOPATHY; MALIGNANT LENTIGO; MEDLINE; MELANOMA; MORPHEA; NONHUMAN; PAGET SKIN DISEASE; PEMPHIGOID; PEMPHIGUS; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; ROSACEA; SKIN ALLERGY; SKIN ATROPHY; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; SKIN IRRITATION; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; SKIN TUMOR; SLEEP DISORDER; SYNCOPE; TERATOGENICITY; URTICARIA; VITILIGO;

ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; SKIN DISEASES;

EID: 4043151534     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin dependent manner. Arch Dermatol Res 1998;290:501-7
2. Nakagawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Torii H, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994;344:883-4.
3. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-21.
4. Darke L, Prendergast M, Maher R, Breneman D, Korman N, Satoi Y, et al. The impact of tacrolimus ointment on health related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001;44(Suppl 1):S65-72.
5. Beklersky I, Fitzsimmons W. Tanse A, Maher RM, Hodosh E, Lawrence I. Non clinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001;44(Suppl 1):S17-27.
6. Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 2000;80:451.
7. McElwee KJ, Rushton DH, Trachy R, Oliver RF. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. Br J Dermatol 1997;137:491-7.
8. Thiers BH. Topical tacrolimus: treatment failure in a patient with alopecia areata. Arch Dermatol 2000;136:124.
9. Lyon CC, Smith AJ, Beck MH, Wong GAE, Griffiths CEA. Parastomal pyoderma gangrenosum: clinical feactures and management. J Am Acad Dermatol 2000;42:992-1002.
10. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999;140:338-42.
11. Choi C, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-versus-host disease: A case series of 18 patients. Arch Dermatol 2001;137:1202-6.
12. Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of contact allergy reactions by topical FK506. Lancet 1992;340:556.
13. Goldman D. Tacrolimus ointment for the treatment of steroid induced rosacea: a preliminary report. J Am Acad Dermatol 2001;44:995-8.
14. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK5O6 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002;12: 50-2.
15. Suga Y, Tsuboi R, Hashimoto Y, Yoshiike T, Ogawa H. A case of ichthyosis linearis circumflexa successfully treated with topical tacrolimus. J Am Acad Dermatol 2000;42:520-2.
16. Schuppe H, Richter-Hintz D, Stierle HE, Homey B, Ruzicka T, Lehmann P. Topical tacrolimus for recalcitrant leg ulcers in rheumatoid arthritis. Rheumatology 2000;39:105-6.
17. Soter NA, Fleischer AB, Webster OF. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001;44(Suppl 1):S39-46.
18. Erdogan M, Wright JR Jr, McAlister VC. Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol 2002:146:964-7.
19. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998:14:805-9.
20. Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-94.
21. Mrowietz U, Graeber M, Brautigam M. Thurston M, Wagenaar A, Weidinger G. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-6.
22. Queille-Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, de Cuyper C. et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000;42:349-5O.
23. Meingassner JG. Stutz A. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for the treatment of skin diseases? J Invest Dermatol 1992;98:851-5.
24. Mollison KW, Fey TA, Gauvin DM, Kolano RM, Sheets MP, Smith ML. et al. A macrolactam inhibitor of T-helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. J Invest Dermatol 1999;112: 729-38.
25. Mahrle G, Schulze HJ. Cyclosporine A- dermatologic indications. Z Hautkr 1990;65:28-9.
26. Bunse T, Schulze HJ, Mahrle G. Topical administration of cyclosporin in psoriasis vulgaris. Z Hautkr 1990;65:538-42.
27. Duncan JI, Wakeel RA, Winfield AJ, Ormerod AD, Thomson AW. Immunomodulation of psoriasis with a topical cyclosporin A formulation. Acta Derm Venereol 1993;73:84-7.
28. Gilhar A, Pillar T, Etzioni A. Topical cyclosporin A in alopecia areata. Acta Derm Venereol (Stockh) 1989;69:252-3.
29. Deprost Y, Teillac F, Paquez C, Carrugi L, Bachelez H, Touraine R. Placebo-controled trial of topical cyclosporin in severe alopecia areata. Lancet 1986;2:803-4.
30. Frances C, Boisnic S, Etienne S, Szpirglas H. Effect of oral application of cyclosporin A on chronic erosive lichen planus of oral cavity. Dermatologica 1988;177:194-5.
31. Eisen D, Ellis CN, Duell EA. Griffiths CE, Voorhees JJ. Effects of topical cyclosporin rinse in oral lichen planus: a double-blind study analysis. N Engl J Med 1990;323:290-4.
32. Becherel PA, Chosidow O, Boisnic S, Reigneau O, Frances C. Topical cyclosporine in the treatment of oral and vulvar erosive lichen planus: A blood level monitoring study. Arch Dermatol 1995;131:495-6.
33. Gooptu C, Staughton RCD. Use of topical cyclosporin in oral pemphigus. J Am Acad Dermatol 1998;38:860-1.
34. Eisen D, Ellis CN. Effect of topical cyclosporin for oral mucosal disorders. J Am Acad Dermatol 1990;23:1259-64.
35. Ergun T, Gurbuz O, Yurdakul S, Hamuryudan V, Bekiroglu N, Yazici H, et al. Topical cyclosporine A for treatment of oral ulcers of Behcet's syndrome. Int J Dermatol 1997;36:717-20.
36. Duffil MB. Cyclosporine, azathioprine and local therapy for pyoderma gangrenosum. Australas J Dermatol 1994;35:15-8.
37. Jitsukawa K, Ring J, Weyer U, Kimmig W, Radloff H, Topical cyclosporine in chronic familial pemphigus (Hailey-Hailey disease). J Am Acad Dermatol 1992;27:625-6.
38. MacDonald Hull S, Cunliffe WJ. Alopecia areata treated with diphencyprone: Is an allergic response necessary? Br J Dermatol 1990;122:716-7.
39. Van der Steen PHM, Van Baar MJ, Perret CM, Happle R. Treatment of alopecia areata with diphencyclopropenone. J Am Acad Dermatol 1991;24:253-7.
40. Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in alopecia areata. J Am Acad Dermatol 1998;39:751-61.
41. Sharma VK, Muralidhar S. Topical immunotherapy with diphencyprone in Indians with alopecia areata. Clin Exp Dermatol 1998;23:291.
42. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model of immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001;137:1063-8.
43. Mc Donald Hull S, Cunliffe WJ. Post therapy relapse rate in alopecia areata after successful treatment with diphencyprone. J Dermatol Treat 1989;1:71-4.
44. Buckley DA, Keane FM, Munn SE, Fuller LC, Higgins EM, Du Vivier AW. Recalcitrant viral warts treated with diphencyprone immunotherapy. Br J Dermatol 1999;141:292-6.
45. Harland CC, Saihan EM. Regression of metastatic malignant melanoma with topical diphencyprone and oral cimetidine. Lancet 1989;2:445.
46. MacDonald N, Wiseman MC, Shapiro J. Alopecia areata: Topical immunotherapy application and practical problems. J Cutan Med Surg 1999;3(Suppl 3):S3-36.
47. Micali G, Cicero RL, Nasca MR, Sapuppo A. Treatment of alopecia areata with squaric acid dibutyl ester. Int J Dermatol 1996;35:52-6.
48. Barth JH, Darley CR, Gibson JR. Squaric acid dibutyl ester in the treatment of alopecia areata. Dermatologica 1985;170:40-2.
49. Van der Steen PHM, Happle R. The 'castling' phenomenon in topical immunotherapy of alopecia areata. Eur J Dermatol 1992;2:151-3.
50. Iijima S, Otsuka F. Contact immunotherapy with squaric acid dibutyl ester for warts. Dermatology 1993;187:115-8.
51. Dunagin WG, Millikan LE. Dinitrochlorobenzene immunotherapy for verrucae resistant to standard treatment modalities. J Am Acad Dermatol 1982;6:40-5.
52. Kumar B, Kaur S. Alopecia areata and dinitrochlorobenzene (DNCB). Indian J Dermatol Venereol Leprol 1980;46:201-2.
53. Singla S, Mittal RR, Walia RLS. Comparative efficacy of topical DNCB and PUVASOL therapy in alopecia areata. Indian J Dermatol Venereol Leprol 1991;57:284-6.
54. Shah KC, Raksha MP. Immunotherapy of condyloma acuminata with dinitrochlorobenzene. Indian J Dermatol Venereol Leprol 1990;56:438-40.
55. Sigg C, Schnyder UW. Successful immunotherapy by dinitrochlorobenzene in a case of recurrent acrotentiginous melanoma. Dermatologica 1990;181:250-1.
56. Traub A, Margulis SB, Stricker RB. Topical immune modulation with dinitrochlorobenzene in HIV disease: a controlled trial from Brazil. Dermatology 1997;195:369-73.
57. Srticker RB, Goldberg B, Mills BL, Epstein WL. Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene. J Am Acad Dermatol 1995;33:608-11.
58. Mills LB, Mordon LJ, Roth HL, Winger EE, Epstein WL. Treatment of severe atopic dermatitis by topical immune modulation using dinitrochlorobenzene. J Am Acad Dermatol 2000;42:687-9.
59. Stricker RB, Goldberg B, Epstein WL. Immunologic changes in patients with systemic lupus erythematosus treated with dinitrochlorobenzene. Lancet 1995;345:1595-6.
60. Kano Y, Otake Y, Shiohara T. Improvement of lichen nitidus after topical dinitrochlorobenzene application. J Am Acad Dermatol 1998;39:305-8.
61. Yoshizawa Y, Kitamura K, Maibach HI. Successful immunotherapy of chronic nodular prurigo with topical dinitrochlorobenzene. Br J Dermatol 1999;141:387-9.
62. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30.
63. Hengge UR, Esser S, Schultewolter T, Behrendt C, Meyer T, Stockfleth E, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000;143:1026-31.
64. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alpha-2b injections. J Am Acad Dermatol 1997;37:755-7.
65. Berman B, Kaufman J. The effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. Poster presented at 59th American Academy of Dermatology 2001.
66. Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%. A report of 6 cases. Br J Dermatol 2001;144:1050-3.
67. Mackenzie-Wood A, Kossard S, de Launey J. Safety and efficacy trial evaluating Imiquimod 5% cream in Bowen's disease with once daily application. J Am Acad Dermatol 2001;44:462-70.
68. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000;143:843-5.
69. Zampognia J, Flowers F, Roth W. Treatment of primary limited cutaneous extra mammary paget's disease with topical imiquimod monotherapy. J Am Acad Dermatol (in press)
70. Marks R, Geisse JK, Owens ML. Imiquimod 5% cream for 12 weeks treating superficial basal cell carcinoma. Poster presented at 8th World Congress on cancers of the skin. 2001.
71. Marks R. Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.
72. Petrow W, Gerdsen R, Uerlich M, Richter O, Bieber T. Successful topical immunotherapy of Bowenoid papulosis with imiquimod. Br J Dermatol 2001;145:1022-3.
73. Miller R. Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors. Int J Dermatol 2002;41(Suppl 1):3-6.
74. Van de Kerkhof PCM. In vivo effects of vitamin D3 analogues. J Dermatol Treat 1998;9:S25-9.
75. Fogh K, Kragballe K. Vitamin D3 analogues. Clin Dermatol 1997;15:705-13.
76. Jain S, Sehgal VN. Psoriasis and calcipotriol. Int J Dermatol 1997;36:255-8.
77. Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998;197:167-70.
78. Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol 1994;130:675-8.
79. Micali G, Nasca MR, Musumeci ML. Effect of topical calcipotriol on inflammatory linear verrucous epidermal nevus. Pediatr Dermatol 1995;12:386-7.
80. Kragballe K, Steijlen PM, Ibsen HH, van de Kerkhof PC, Esmann J, Sorensen LH, et al. Efficacy, tolerability and safety of calcipotriol ointment in disorders of keratinization. Results of randomized, double blind, vehicle controlled, right/left comparative study. Arch Dermatol 1995;131:556-60.
81. Bohm M, Luger TA. Metze D. Treatment of mixed-type acanthosis nigricans with topical calcipotriol. Br J Dermatol 1998;139:932-4.
82. Cunningham BB, Landells ID, Langman C, Sailer DE. Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998;39:211-5.
83. Wong SS, Goh CL. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of prurigo nodularis. Arch Dermatol 2000;136:807-8.
84. Khoo BP, Tay YK, Goh CL. Calcipotriol ointment vs. betamethasone- 17 valerate ointment in the treatment of lichen amyloidosis. Int J Dermatol 1999;38:539-41.
85. Keohane SG, Cork MJ. Treatment of Grover's disease with calcipotriol (Dovonex). Br J Dermatol 1995;132:832-3.
86. Kurkcuoglu N, Celebi CR. Confluent and reticulate papillomatosis: response to topical calcipotriol. Dermatology 1995;191:341-2.
87. Grunwald MH, Hallel-Halevy D, Amichai B. Keratosis lichenoides chronica: response to topical calcipotriol. J Am Acad Dermatol 1997;37:263-4.
88. Ashton RE, Andre P, Lowe NJ, Whitefield M. Anthralin: Historical and current perspective. J Am Acad Dermatol 1983;9:173-92.
89. Fiedler-Weiss V, Buys C. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987;123:1491.
90. Kaur I, Kaur S, Sharma VK, Singh M, Kumar B.. Modified dithranol therapy for psoriasis. Indian J Dermatol Venereol Leprol 1985;51:90-3.
91. Kar PK, Jha PK, Snehi PS. Anthralin short contact therapy in psoriasis. Indian J Dermatol Venereol Leprol 1990;56:193-5.
92. Fiedler V, Vendrow A, Szunpar G, Metzler C, DeVillez RL. Treatment resistant alopecia areata. Arch Dermatol 1990;126:756.
93. Thomas J, Kandhari S, Oberoi C, Jayaseelan E, Yogi Raj K. A double-blind randomized multicentre controlled study of topical 0.05% clobetasol propionate with 2.5% zinc sulphate preparation. Indian J Dermatol Venereol Leprol 2001;67:135-7.
94. Magnus S, Hendrick H, Agren. Zinc oxide augments endogenous expression of insulin like growth factor I (IGF-I) and activates matrix metalloproteinases (MMPS) in wounds. EMWA Journal 2001;1:1-3.
95. Shupack J, Stiler M, Davis I, Kenny C, Jondreau L. Topical alpha-interferon ointment with dimethyl sulfoxide in the treatment of recurrent genital herpes simplex. Dermatology 1992;184:40-4.
96. Edwards L, Levine N, Smiles KA. The effect of topical interferon-a2b on actinic keratoses. J Dermatol Surg Oncol 1990;16:446-9.
97. Harms G, Chehade AK, Rach P, Talhari S, Racz P, Mouakeh A, et al. Effects of intradermal gamma interferon in cutaneous leishmaniasis. Lancet 1989;1:1287-92.
98. Vance JC, Bart BJ. Hansen RC, Talhari S, Racz P, Mouakeh A, et al. Intralesional recombinant-a2a interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986;122:272-7.
99. Kowalzick L, Rogozinski T, Wimheuer R, Pilz J, Manske U, Scholz A, et al. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open label multicentre study. Eur J Dermatol 2002;12:558-61.
100. Edwards L, Berman B, Rapini RP, Whiting DA, Tyring S, Greenway HT Jr, et al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon - a2b therapy. Arch Dermatol 1992;128:1486-9.
101. Martinez J, de Misa RF, Torrelo A, Ledo A. Low dose intralesional interferon -a for discoid lupus erythematosus. J Am Acad Dermatol 1992;26:494-6.
102. Rampini E, Pampini P, Occella C, Bleidl D. Interferon - a2b for treatment of complex cutaneous hemangiomas of infancy: a reduced dosage schedule. Br J Dermatol 2000;142:189-91.
103. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985-90.